Novartis AG - Company Snapshot & SWOT Analysis
Novartis AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland, ranking number one in sales (50.13 billion US$) among the world-wide industry in 2017. On July 10 2015, Novartis became the largest Healthcare company by market capitalization, during intra-day trading, with a market-cap of $279.8 billion in comparison to Johnson & Johnson at $276.3 billion.
Novartis AG reported revenue of USD 51.90 billion for the FY 2018 which saw an increase of 5.68% compared to FY 2017. Novartis also announced that the spin-off of Alcon is still on-track, with the company awaiting the final endorsement of the move within the first half of the year.According to company statement , 'Alcon is positioned for sustainable long-term top-line growth and margin expansion as demonstrated by the strong 2018 results,” Alcon division's total sale in 2018 was USD 7.14 Billion.
Spanning over 31 pages and 16 exhibits, “Novartis AG - Company Snapshot & SWOT Analysis” report provides value chain analysis, financial performance, business strategy and SWOT analysis for company.
Scope of the Novartis AG- Company Snapshot & SWOT Analysis Report
Novartis AG reported revenue of USD 51.90 billion for the FY 2018 which saw an increase of 5.68% compared to FY 2017. Novartis also announced that the spin-off of Alcon is still on-track, with the company awaiting the final endorsement of the move within the first half of the year.According to company statement , 'Alcon is positioned for sustainable long-term top-line growth and margin expansion as demonstrated by the strong 2018 results,” Alcon division's total sale in 2018 was USD 7.14 Billion.
Spanning over 31 pages and 16 exhibits, “Novartis AG - Company Snapshot & SWOT Analysis” report provides value chain analysis, financial performance, business strategy and SWOT analysis for company.
Scope of the Novartis AG- Company Snapshot & SWOT Analysis Report
- This report provides detailed information about Novartis AG including value chain analysis, financial performance, business strategy and SWOT analysis.
- The report identifies the growth drivers and inhibitors for global pharmaceutical market.
- This report provides information about current and future trends for global pharmaceutical market.
1. EXECUTIVE SUMMARY
Scope of the Novartis AG- Company Snapshot & SWOT Analysis Report
Research Methodology
2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET
3. COMPANY PROFILE
3.1 Novartis AG
3.1.1 Company Profile
3.2.2 Novartis AG in Global Pharmaceuticals Manufacturing Value Chain
3.2.3 Novartis AG: Financial Performance
3.2.3.1 Novartis AG: Overall Revenue FY 2013-FY 2019 (in USD billion)
3.2.3.2 Novartis AG: Geography-Wise Revenue FY 2018 (in USD billion)
3.2.3.3 Novartis AG: Therapy Area-Wise Revenue FY 2018 (in USD billion)
3.2.4 Novartis AG: Business Strategy
3.2.5 SWOT Analysis of Novartis AG
Strengths
Weaknesses
Opportunities
Threats
4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET
Company Information
List of Exibits
Scope of the Novartis AG- Company Snapshot & SWOT Analysis Report
Research Methodology
2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET
3. COMPANY PROFILE
3.1 Novartis AG
3.1.1 Company Profile
3.2.2 Novartis AG in Global Pharmaceuticals Manufacturing Value Chain
3.2.3 Novartis AG: Financial Performance
3.2.3.1 Novartis AG: Overall Revenue FY 2013-FY 2019 (in USD billion)
3.2.3.2 Novartis AG: Geography-Wise Revenue FY 2018 (in USD billion)
3.2.3.3 Novartis AG: Therapy Area-Wise Revenue FY 2018 (in USD billion)
3.2.4 Novartis AG: Business Strategy
3.2.5 SWOT Analysis of Novartis AG
Strengths
Weaknesses
Opportunities
Threats
4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET
Company Information
List of Exibits
LIST OF EXHIBITS
Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 3.1 Key Information of Novartis AG
Exhibit 3.2 Contact Information of Novartis AG
Exhibit 3.3 Novartis AG in Pharmaceuticals Manufacturing Value Chain
Exhibit 3.4 Revenue of Novartis AG FY 2013- FY 2019 (in USD billion)
Exhibit 3.5 Revenue Growth of Novartis AG FY 2014- FY 2019 (in %)
Exhibit 3.6 Geography-Wise Revenue of Novartis AG in FY 2018 (in USD billion)
Exhibit 3.7 Therapy and Geography Area-Wise Revenue of Pfizer Inc. FY 2018 (in USD million)
Exhibit 3.8 Business Division-Wise Revenue of Novartis AG in FY 2018 (in USD million)
Exhibit 3.9 Pharmaceutical Segment Revenue of Novartis AG in FY 2018 (in USD million)
Exhibit 3.10 Innovative Medicines Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 3.11 Sandoz Division Revenue of Novartis AG in FY 2018 (in USD million)
Exhibit 3.12 Sandoz Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 3.13 Alcon Division Revenue of Novartis AG in FY 2018 (in USD million)
Exhibit 3.14 Alcon Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 3.15 10+ potential blockbuster launches planned by Novartis AG in the next 2 years
Exhibit 3.16 SWOT Analysis of Novartis AG
Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 3.1 Key Information of Novartis AG
Exhibit 3.2 Contact Information of Novartis AG
Exhibit 3.3 Novartis AG in Pharmaceuticals Manufacturing Value Chain
Exhibit 3.4 Revenue of Novartis AG FY 2013- FY 2019 (in USD billion)
Exhibit 3.5 Revenue Growth of Novartis AG FY 2014- FY 2019 (in %)
Exhibit 3.6 Geography-Wise Revenue of Novartis AG in FY 2018 (in USD billion)
Exhibit 3.7 Therapy and Geography Area-Wise Revenue of Pfizer Inc. FY 2018 (in USD million)
Exhibit 3.8 Business Division-Wise Revenue of Novartis AG in FY 2018 (in USD million)
Exhibit 3.9 Pharmaceutical Segment Revenue of Novartis AG in FY 2018 (in USD million)
Exhibit 3.10 Innovative Medicines Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 3.11 Sandoz Division Revenue of Novartis AG in FY 2018 (in USD million)
Exhibit 3.12 Sandoz Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 3.13 Alcon Division Revenue of Novartis AG in FY 2018 (in USD million)
Exhibit 3.14 Alcon Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 3.15 10+ potential blockbuster launches planned by Novartis AG in the next 2 years
Exhibit 3.16 SWOT Analysis of Novartis AG
